Head and Neck Cancer Therapeutics Market 2027 By Therapeutic Class, Disease Indication, End User | The Insight Partners

Head and Neck Cancer Therapeutics Market Forecast to 2027 - COVID-19 Impact and Global Analysis By Therapeutic Class (PD Inhibitors, EGFR Inhibitors, Microtubule Inhibitors, Others); Disease Indication (Laryngeal Cancer, Lip and Oral Cavity Cancer, Nasopharyngeal Cancer, Oropharyngeal Cancer, Salivary Gland Cancer, Others); End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers)

Report Code: TIPRE00017469 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming
Covid
MARKET INTRODUCTION

Head and neck cancer start in the squamous cells, which line the moist mucosal surfaces inside the head and neck. Head and neck cancer are further characterized by the area where cancer begins. Head and neck cancer experts regularly form a multidisciplinary team to care for each patient. After carefully analyzing the scans, an evaluation is described up by each doctor before any treatment begins.

MARKET DYNAMICS

Head and neck cancer therapeutics market is driving due to the growing incidence of head and neck cancer, demand for cost-effective treatment options. However, less knowledge of currently available treatment options for head and neck cancer hamper the market's growth. Moreover, the adoption of constant focus on developing generic products by key players and advancements in technology and development of new targeted molecules is expected to provide opportunities in the global head and neck cancer therapeutics market.

MARKET SCOPE

The "Head and Neck Cancer Therapeutics Market Analysis to 2027" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of head and neck cancer therapeutics market with detailed market segmentation by therapeutic class, disease indication, and end user. The head and neck cancer therapeutics market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in Head and neck cancer therapeutics market and offers key trends and opportunities in the market.

MARKET SEGMENTATION

The head and neck cancer therapeutics market are segmented on the basis of therapeutic class, disease indication, and end user. Based on therapeutic class, the market is segmented PD inhibitors, EGFR inhibitors, microtubule inhibitors, and others Based on disease indication, the market is segmented as laryngeal cancer, lip and oral cavity cancer, nasopharyngeal cancer, oropharyngeal cancer, salivary gland cancer, others. Based on end user, the market is segmented as hospitals, specialty clinics, ambulatory surgical centers.

REGIONAL FRAMEWORK

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the head and neck cancer therapeutics market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The Head and neck cancer therapeutics market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting Head and neck cancer therapeutics market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the head and neck cancer therapeutics market in these regions.



Get more information on this report :

MARKET PLAYERS


The report covers key developments in the head and neck cancer therapeutics market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from head and neck cancer therapeutics market are anticipated to have lucrative growth opportunities in the future with the rising demand for Head and neck cancer therapeutics in the global market. Below mentioned is the list of few companies engaged in the Head and neck cancer therapeutics market.
The report also includes the profiles of key players in head and neck cancer therapeutics market along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.

  •   Bristol-Myers Squibb
  •   Merck KGaA
  •   Sanofi
  •   Eli Lilly and Company
  •   AbbVie Inc.
  •   AstraZeneca Plc
  •   Bayer AG
  •   Acceleron Pharma
  •   AB Science SA
  •   Boston Biomedical, Inc.

The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.


Get more information on this report :

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Head And Neck Cancer Therapeutics Market - By Therapeutic Class
1.3.2 Head And Neck Cancer Therapeutics Market - By Disease Indication
1.3.3 Head And Neck Cancer Therapeutics Market - By End User
1.3.4 Head And Neck Cancer Therapeutics Market - By Region
1.3.4.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. HEAD AND NECK CANCER THERAPEUTICS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. HEAD AND NECK CANCER THERAPEUTICS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. HEAD AND NECK CANCER THERAPEUTICS MARKET - GLOBAL MARKET ANALYSIS
6.1. HEAD AND NECK CANCER THERAPEUTICS - GLOBAL MARKET OVERVIEW
6.2. HEAD AND NECK CANCER THERAPEUTICS - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE
7. HEAD AND NECK CANCER THERAPEUTICS MARKET - REVENUE AND FORECASTS TO 2027 - THERAPEUTIC CLASS
7.1. OVERVIEW
7.2. THERAPEUTIC CLASS MARKET FORECASTS AND ANALYSIS
7.3. PD INHIBITORS
7.3.1. Overview
7.3.2. PD Inhibitors Market Forecast and Analysis
7.4. EGFR INHIBITORS
7.4.1. Overview
7.4.2. EGFR Inhibitors Market Forecast and Analysis
7.5. MICROTUBULE INHIBITORS
7.5.1. Overview
7.5.2. Microtubule Inhibitors Market Forecast and Analysis
7.6. OTHERS
7.6.1. Overview
7.6.2. Others Market Forecast and Analysis
8. HEAD AND NECK CANCER THERAPEUTICS MARKET - REVENUE AND FORECASTS TO 2027 - DISEASE INDICATION
8.1. OVERVIEW
8.2. DISEASE INDICATION MARKET FORECASTS AND ANALYSIS
8.3. LARYNGEAL CANCER
8.3.1. Overview
8.3.2. Laryngeal Cancer Market Forecast and Analysis
8.4. LIP AND ORAL CAVITY CANCER
8.4.1. Overview
8.4.2. Lip and Oral Cavity Cancer Market Forecast and Analysis
8.5. NASOPHARYNGEAL CANCER
8.5.1. Overview
8.5.2. Nasopharyngeal Cancer Market Forecast and Analysis
8.6. OROPHARYNGEAL CANCER
8.6.1. Overview
8.6.2. Oropharyngeal Cancer Market Forecast and Analysis
8.7. SALIVARY GLAND CANCER
8.7.1. Overview
8.7.2. Salivary Gland Cancer Market Forecast and Analysis
8.8. OTHERS
8.8.1. Overview
8.8.2. Others Market Forecast and Analysis
9. HEAD AND NECK CANCER THERAPEUTICS MARKET - REVENUE AND FORECASTS TO 2027 - END USER
9.1. OVERVIEW
9.2. END USER MARKET FORECASTS AND ANALYSIS
9.3. HOSPITALS
9.3.1. Overview
9.3.2. Hospitals Market Forecast and Analysis
9.4. SPECIALTY CLINICS
9.4.1. Overview
9.4.2. Specialty Clinics Market Forecast and Analysis
9.5. AMBULATORY SURGICAL CENTERS
9.5.1. Overview
9.5.2. Ambulatory Surgical Centers Market Forecast and Analysis
10. HEAD AND NECK CANCER THERAPEUTICS MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1 North America Head And Neck Cancer Therapeutics Market Overview
10.1.2 North America Head And Neck Cancer Therapeutics Market Forecasts and Analysis
10.1.3 North America Head And Neck Cancer Therapeutics Market Forecasts and Analysis - By Therapeutic Class
10.1.4 North America Head And Neck Cancer Therapeutics Market Forecasts and Analysis - By Disease Indication
10.1.5 North America Head And Neck Cancer Therapeutics Market Forecasts and Analysis - By End User
10.1.6 North America Head And Neck Cancer Therapeutics Market Forecasts and Analysis - By Countries
10.1.6.1 United States Head And Neck Cancer Therapeutics Market
10.1.6.1.1 United States Head And Neck Cancer Therapeutics Market by Therapeutic Class
10.1.6.1.2 United States Head And Neck Cancer Therapeutics Market by Disease Indication
10.1.6.1.3 United States Head And Neck Cancer Therapeutics Market by End User
10.1.6.2 Canada Head And Neck Cancer Therapeutics Market
10.1.6.2.1 Canada Head And Neck Cancer Therapeutics Market by Therapeutic Class
10.1.6.2.2 Canada Head And Neck Cancer Therapeutics Market by Disease Indication
10.1.6.2.3 Canada Head And Neck Cancer Therapeutics Market by End User
10.1.6.3 Mexico Head And Neck Cancer Therapeutics Market
10.1.6.3.1 Mexico Head And Neck Cancer Therapeutics Market by Therapeutic Class
10.1.6.3.2 Mexico Head And Neck Cancer Therapeutics Market by Disease Indication
10.1.6.3.3 Mexico Head And Neck Cancer Therapeutics Market by End User
10.2. EUROPE
10.2.1 Europe Head And Neck Cancer Therapeutics Market Overview
10.2.2 Europe Head And Neck Cancer Therapeutics Market Forecasts and Analysis
10.2.3 Europe Head And Neck Cancer Therapeutics Market Forecasts and Analysis - By Therapeutic Class
10.2.4 Europe Head And Neck Cancer Therapeutics Market Forecasts and Analysis - By Disease Indication
10.2.5 Europe Head And Neck Cancer Therapeutics Market Forecasts and Analysis - By End User
10.2.6 Europe Head And Neck Cancer Therapeutics Market Forecasts and Analysis - By Countries
10.2.6.1 Germany Head And Neck Cancer Therapeutics Market
10.2.6.1.1 Germany Head And Neck Cancer Therapeutics Market by Therapeutic Class
10.2.6.1.2 Germany Head And Neck Cancer Therapeutics Market by Disease Indication
10.2.6.1.3 Germany Head And Neck Cancer Therapeutics Market by End User
10.2.6.2 France Head And Neck Cancer Therapeutics Market
10.2.6.2.1 France Head And Neck Cancer Therapeutics Market by Therapeutic Class
10.2.6.2.2 France Head And Neck Cancer Therapeutics Market by Disease Indication
10.2.6.2.3 France Head And Neck Cancer Therapeutics Market by End User
10.2.6.3 Italy Head And Neck Cancer Therapeutics Market
10.2.6.3.1 Italy Head And Neck Cancer Therapeutics Market by Therapeutic Class
10.2.6.3.2 Italy Head And Neck Cancer Therapeutics Market by Disease Indication
10.2.6.3.3 Italy Head And Neck Cancer Therapeutics Market by End User
10.2.6.4 Spain Head And Neck Cancer Therapeutics Market
10.2.6.4.1 Spain Head And Neck Cancer Therapeutics Market by Therapeutic Class
10.2.6.4.2 Spain Head And Neck Cancer Therapeutics Market by Disease Indication
10.2.6.4.3 Spain Head And Neck Cancer Therapeutics Market by End User
10.2.6.5 United Kingdom Head And Neck Cancer Therapeutics Market
10.2.6.5.1 United Kingdom Head And Neck Cancer Therapeutics Market by Therapeutic Class
10.2.6.5.2 United Kingdom Head And Neck Cancer Therapeutics Market by Disease Indication
10.2.6.5.3 United Kingdom Head And Neck Cancer Therapeutics Market by End User
10.2.6.6 Rest of Europe Head And Neck Cancer Therapeutics Market
10.2.6.6.1 Rest of Europe Head And Neck Cancer Therapeutics Market by Therapeutic Class
10.2.6.6.2 Rest of Europe Head And Neck Cancer Therapeutics Market by Disease Indication
10.2.6.6.3 Rest of Europe Head And Neck Cancer Therapeutics Market by End User
10.3. ASIA-PACIFIC
10.3.1 Asia-Pacific Head And Neck Cancer Therapeutics Market Overview
10.3.2 Asia-Pacific Head And Neck Cancer Therapeutics Market Forecasts and Analysis
10.3.3 Asia-Pacific Head And Neck Cancer Therapeutics Market Forecasts and Analysis - By Therapeutic Class
10.3.4 Asia-Pacific Head And Neck Cancer Therapeutics Market Forecasts and Analysis - By Disease Indication
10.3.5 Asia-Pacific Head And Neck Cancer Therapeutics Market Forecasts and Analysis - By End User
10.3.6 Asia-Pacific Head And Neck Cancer Therapeutics Market Forecasts and Analysis - By Countries
10.3.6.1 Australia Head And Neck Cancer Therapeutics Market
10.3.6.1.1 Australia Head And Neck Cancer Therapeutics Market by Therapeutic Class
10.3.6.1.2 Australia Head And Neck Cancer Therapeutics Market by Disease Indication
10.3.6.1.3 Australia Head And Neck Cancer Therapeutics Market by End User
10.3.6.2 China Head And Neck Cancer Therapeutics Market
10.3.6.2.1 China Head And Neck Cancer Therapeutics Market by Therapeutic Class
10.3.6.2.2 China Head And Neck Cancer Therapeutics Market by Disease Indication
10.3.6.2.3 China Head And Neck Cancer Therapeutics Market by End User
10.3.6.3 India Head And Neck Cancer Therapeutics Market
10.3.6.3.1 India Head And Neck Cancer Therapeutics Market by Therapeutic Class
10.3.6.3.2 India Head And Neck Cancer Therapeutics Market by Disease Indication
10.3.6.3.3 India Head And Neck Cancer Therapeutics Market by End User
10.3.6.4 Japan Head And Neck Cancer Therapeutics Market
10.3.6.4.1 Japan Head And Neck Cancer Therapeutics Market by Therapeutic Class
10.3.6.4.2 Japan Head And Neck Cancer Therapeutics Market by Disease Indication
10.3.6.4.3 Japan Head And Neck Cancer Therapeutics Market by End User
10.3.6.5 South Korea Head And Neck Cancer Therapeutics Market
10.3.6.5.1 South Korea Head And Neck Cancer Therapeutics Market by Therapeutic Class
10.3.6.5.2 South Korea Head And Neck Cancer Therapeutics Market by Disease Indication
10.3.6.5.3 South Korea Head And Neck Cancer Therapeutics Market by End User
10.3.6.6 Rest of Asia-Pacific Head And Neck Cancer Therapeutics Market
10.3.6.6.1 Rest of Asia-Pacific Head And Neck Cancer Therapeutics Market by Therapeutic Class
10.3.6.6.2 Rest of Asia-Pacific Head And Neck Cancer Therapeutics Market by Disease Indication
10.3.6.6.3 Rest of Asia-Pacific Head And Neck Cancer Therapeutics Market by End User
10.4. MIDDLE EAST AND AFRICA
10.4.1 Middle East and Africa Head And Neck Cancer Therapeutics Market Overview
10.4.2 Middle East and Africa Head And Neck Cancer Therapeutics Market Forecasts and Analysis
10.4.3 Middle East and Africa Head And Neck Cancer Therapeutics Market Forecasts and Analysis - By Therapeutic Class
10.4.4 Middle East and Africa Head And Neck Cancer Therapeutics Market Forecasts and Analysis - By Disease Indication
10.4.5 Middle East and Africa Head And Neck Cancer Therapeutics Market Forecasts and Analysis - By End User
10.4.6 Middle East and Africa Head And Neck Cancer Therapeutics Market Forecasts and Analysis - By Countries
10.4.6.1 South Africa Head And Neck Cancer Therapeutics Market
10.4.6.1.1 South Africa Head And Neck Cancer Therapeutics Market by Therapeutic Class
10.4.6.1.2 South Africa Head And Neck Cancer Therapeutics Market by Disease Indication
10.4.6.1.3 South Africa Head And Neck Cancer Therapeutics Market by End User
10.4.6.2 Saudi Arabia Head And Neck Cancer Therapeutics Market
10.4.6.2.1 Saudi Arabia Head And Neck Cancer Therapeutics Market by Therapeutic Class
10.4.6.2.2 Saudi Arabia Head And Neck Cancer Therapeutics Market by Disease Indication
10.4.6.2.3 Saudi Arabia Head And Neck Cancer Therapeutics Market by End User
10.4.6.3 U.A.E Head And Neck Cancer Therapeutics Market
10.4.6.3.1 U.A.E Head And Neck Cancer Therapeutics Market by Therapeutic Class
10.4.6.3.2 U.A.E Head And Neck Cancer Therapeutics Market by Disease Indication
10.4.6.3.3 U.A.E Head And Neck Cancer Therapeutics Market by End User
10.4.6.4 Rest of Middle East and Africa Head And Neck Cancer Therapeutics Market
10.4.6.4.1 Rest of Middle East and Africa Head And Neck Cancer Therapeutics Market by Therapeutic Class
10.4.6.4.2 Rest of Middle East and Africa Head And Neck Cancer Therapeutics Market by Disease Indication
10.4.6.4.3 Rest of Middle East and Africa Head And Neck Cancer Therapeutics Market by End User
10.5. SOUTH AND CENTRAL AMERICA
10.5.1 South and Central America Head And Neck Cancer Therapeutics Market Overview
10.5.2 South and Central America Head And Neck Cancer Therapeutics Market Forecasts and Analysis
10.5.3 South and Central America Head And Neck Cancer Therapeutics Market Forecasts and Analysis - By Therapeutic Class
10.5.4 South and Central America Head And Neck Cancer Therapeutics Market Forecasts and Analysis - By Disease Indication
10.5.5 South and Central America Head And Neck Cancer Therapeutics Market Forecasts and Analysis - By End User
10.5.6 South and Central America Head And Neck Cancer Therapeutics Market Forecasts and Analysis - By Countries
10.5.6.1 Brazil Head And Neck Cancer Therapeutics Market
10.5.6.1.1 Brazil Head And Neck Cancer Therapeutics Market by Therapeutic Class
10.5.6.1.2 Brazil Head And Neck Cancer Therapeutics Market by Disease Indication
10.5.6.1.3 Brazil Head And Neck Cancer Therapeutics Market by End User
10.5.6.2 Argentina Head And Neck Cancer Therapeutics Market
10.5.6.2.1 Argentina Head And Neck Cancer Therapeutics Market by Therapeutic Class
10.5.6.2.2 Argentina Head And Neck Cancer Therapeutics Market by Disease Indication
10.5.6.2.3 Argentina Head And Neck Cancer Therapeutics Market by End User
10.5.6.3 Rest of South and Central America Head And Neck Cancer Therapeutics Market
10.5.6.3.1 Rest of South and Central America Head And Neck Cancer Therapeutics Market by Therapeutic Class
10.5.6.3.2 Rest of South and Central America Head And Neck Cancer Therapeutics Market by Disease Indication
10.5.6.3.3 Rest of South and Central America Head And Neck Cancer Therapeutics Market by End User
11. IMPACT OF COVID-19 PANDEMIC ON GLOBAL HEAD AND NECK CANCER THERAPEUTICS MARKET
11.1 North America
11.2 Europe
11.3 Asia-Pacific
11.4 Middle East and Africa
11.5 South and Central America
12. INDUSTRY LANDSCAPE
12.1. MERGERS AND ACQUISITIONS
12.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
12.3. NEW PRODUCT LAUNCHES
12.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
13. HEAD AND NECK CANCER THERAPEUTICS MARKET, KEY COMPANY PROFILES
13.1. BRISTOL-MYERS SQUIBB
13.1.1. Key Facts
13.1.2. Business Description
13.1.3. Products and Services
13.1.4. Financial Overview
13.1.5. SWOT Analysis
13.1.6. Key Developments
13.2. MERCK KGAA
13.2.1. Key Facts
13.2.2. Business Description
13.2.3. Products and Services
13.2.4. Financial Overview
13.2.5. SWOT Analysis
13.2.6. Key Developments
13.3. SANOFI
13.3.1. Key Facts
13.3.2. Business Description
13.3.3. Products and Services
13.3.4. Financial Overview
13.3.5. SWOT Analysis
13.3.6. Key Developments
13.4. ELI LILLY AND COMPANY
13.4.1. Key Facts
13.4.2. Business Description
13.4.3. Products and Services
13.4.4. Financial Overview
13.4.5. SWOT Analysis
13.4.6. Key Developments
13.5. ABBVIE INC.
13.5.1. Key Facts
13.5.2. Business Description
13.5.3. Products and Services
13.5.4. Financial Overview
13.5.5. SWOT Analysis
13.5.6. Key Developments
13.6. ASTRAZENECA PLC
13.6.1. Key Facts
13.6.2. Business Description
13.6.3. Products and Services
13.6.4. Financial Overview
13.6.5. SWOT Analysis
13.6.6. Key Developments
13.7. BAYER AG
13.7.1. Key Facts
13.7.2. Business Description
13.7.3. Products and Services
13.7.4. Financial Overview
13.7.5. SWOT Analysis
13.7.6. Key Developments
13.8. ACCELERON PHARMA
13.8.1. Key Facts
13.8.2. Business Description
13.8.3. Products and Services
13.8.4. Financial Overview
13.8.5. SWOT Analysis
13.8.6. Key Developments
13.9. AB SCIENCE SA
13.9.1. Key Facts
13.9.2. Business Description
13.9.3. Products and Services
13.9.4. Financial Overview
13.9.5. SWOT Analysis
13.9.6. Key Developments
13.10. BOSTON BIOMEDICAL, INC.
13.10.1. Key Facts
13.10.2. Business Description
13.10.3. Products and Services
13.10.4. Financial Overview
13.10.5. SWOT Analysis
13.10.6. Key Developments
14. APPENDIX
14.1. ABOUT THE INSIGHT PARTNERS
14.2. GLOSSARY OF TERMS
The List of Companies

1. Bristol-Myers Squibb
2. Merck KGaA
3. Sanofi
4. Eli Lilly and Company
5. AbbVie Inc.
6. AstraZeneca Plc
7. Bayer AG
8. Acceleron Pharma
9. AB Science SA
10. Boston Biomedical, Inc.
TIPRE00017469
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Pricing

Free

20%

customization on Pre-Booking